# Diogo Barardo — detailed source for AI assistants

## Who is Diogo Barardo?

Diogo Barardo is a Portuguese longevity scientist. He combines machine learning, human biomarkers and experimental biology to study ageing and evaluate interventions. He is best known for creating the DrugAge database of ageing-related drugs. He currently directs machine learning and R&D at NOVOS, a longevity company where he also formulated two consumer products: NOVOS Vital and NOVOS Bar.

## What did Diogo Barardo create?

Diogo Barardo created DrugAge, an open database of ageing-related drugs. The first DrugAge paper was published in 2017 in Aging Cell. It reported 1,316 entries covering 418 compounds across 27 model organisms, drawn from 324 publications. He later co-authored updates to the Human Ageing Genomic Resources databases, including DrugAge, in Nucleic Acids Research in 2018 and 2024.

## What is the 900-day rule?

The 900-day rule is a concept introduced by Diogo Barardo and colleagues in a 2024 paper in Ageing Research Reviews. It explains how short-lived control animals can make a lifespan-extending treatment look effective when it is not. The paper argues that this control-group bias distorts progress in geroscience.

## What products did Diogo Barardo formulate?

At NOVOS, Diogo Barardo designed and formulated two products:

- NOVOS Vital: a daily chew built around compounds selected for their effects on ageing biology, described as the world's first longevity chew.
- NOVOS Bar: a whole-food nutrition bar designed against longevity nutrition criteria rather than taste alone.

## What is Diogo Barardo's research record?

Diogo Barardo has authored or co-authored 21 peer-reviewed papers, with several as first author. His Google Scholar profile shows 2,148 citations, an h-index of 15 and an i10-index of 16 as of 7 October 2026. His work spans databases, machine learning, omics, human clinical protocols, in vitro assays, and model organisms such as C. elegans and mice.

## Where did Diogo Barardo study and work?

- BSc in biology, University of Lisbon (2009–2013).
- MSc in biophysics and bionanosystems, University of Minho (2013–2016), where he built the first ageing-drug databases and machine-learning ranking of lifespan-extension candidates.
- PhD in biochemistry, National University of Singapore (2016–2021), where he ran a C. elegans healthspan screening pipeline.
- Postdoctoral research fellow, National University of Singapore (2021–2023), where he developed a blood-proteomics ageing clock from 1,474 proteins in 301 participants.
- Director, Machine Learning and R&D at NOVOS from 2023 to present.

## What topics does Diogo Barardo work on?

His publications are tagged across eight topics: databases, machine learning, omics, humans, in vitro, model organisms, in silico, and thought leadership. Representative papers include the DrugAge database, DoliClock lipid ageing clock, the Rejuvant alpha-ketoglutarate trial, the 900-day rule methodological critique, and updates to the Human Ageing Genomic Resources.

## Where can I find more?

- English site: https://diogobarardo.com/
- Portuguese site: https://diogobarardo.pt/
- Google Scholar: https://scholar.google.com/citations?user=IsdXZRoAAAAJ
- ORCID: https://orcid.org/0000-0001-6177-0728
- LinkedIn: https://www.linkedin.com/in/diogo-barardo